* Apogee Therapeutics (NASDAQ:APGE [https://seekingalpha.com/symbol/APGE]) priced its public offering at $41 per share, raising ~$300M in gross proceeds.
* The offering includes 6.95M common shares and 365,853 pre-funded warrants priced at $41 each.
* Pre-funded warrants are exercisable immediately.
* Offering is expected to close on October 10, 2025.
* Apogee granted underwriters a 30-day option to purchase up to 1.1M additional shares.
* Proceeds will support the company’s clinical-stage biologics pipeline targeting inflammatory and immunology markets.
* Source: Press release [https://seekingalpha.com/pr/20259932-apogee-therapeutics-inc-announces-pricing-of-300-million-underwritten-public-offering]
MORE ON APOGEE THERAPEUTICS
* Apogee Therapeutics announces underwritten public offering [https://seekingalpha.com/news/4502781-apogee-therapeutics-announces-underwritten-public-offering]
* Seeking Alpha’s Quant Rating on Apogee Therapeutics [https://seekingalpha.com/symbol/APGE/ratings/quant-ratings]
* Historical earnings data for Apogee Therapeutics [https://seekingalpha.com/symbol/APGE/earnings]
* Financial information for Apogee Therapeutics [https://seekingalpha.com/symbol/APGE/income-statement]
Apogee Therapeutics prices $300M public offering
Published 1 month ago
Oct 9, 2025 at 6:18 AM
Positive
Auto